Replies to post #10876 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Easka. The orphan drug exclusivity expired .

Patents and Proprietary Rights

The FDA first approved the use of Acthar in 1952, and Acthar is no longer subject to patent protection. Acthar does have orphan drug exclusivity for its infantile spasm indication that extends until October 15, 2017 for that indication only

.

https://www.sec.gov/Archives/edgar/data/891288/000119312514264708/d755101dex991.htm